newsfilter
← Latest News
GlobeNewswire·

Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026

UPB
  • Verekitug 100 mg dosed every 12 weeks reduced annualized asthma exacerbation rate (AAER) by 56% compared to placebo in the Phase 2 VALIANT trial.
  • The treatment demonstrated statistically significant improvements in lung function (FEV1), exhaled nitric oxide (FeNO), \& asthma symptom control (ACQ-6).
  • Upstream Bio plans to initiate Phase 3 trials for severe asthma \& chronic rhinosinusitis with nasal polyps (CRSwNP) in Q1 2027.
  • Phase 3 studies will evaluate a 400 mg quarterly regimen of verekitug in broad patient populations without baseline biomarker restrictions.
  • The VALIANT trial evaluated 478 patients across variable dose arms, with all participants receiving at least 24 weeks of treatment.
  • Verekitug showed a favorable safety profile with no meaningful impact from immunogenicity on safety or efficacy results.
  • The long-term extension study VALOUR completed enrollment in March 2026 with over 90% retention of Phase 2 participants, with data expected in H2 2027.
  • Verekitug is the only known TSLP receptor antagonist currently in clinical development.
  • The company has treated more than 500 participants with verekitug across its clinical programs to date.